A license agreement to develop GUB014295, a possible best-in-class, long-acting amylin analog for the treatment of obesity, was announced by AbbVie and Gubra A/S, a firm that specializes in preclinical contract research services and peptide-based therapeutic discovery within metabolic and fibrotic illnesses.
At AbbVie, we are focused on transforming the future of patient care in areas where significant unmet need persists,
Our partnership with Gubra marks our entry into the obesity field, offering a compelling opportunity based on the potential to address patient needs while also fostering long-term growth for our company.
Robert A. Michael, chief executive officer, AbbVie
Currently, a Phase 1 clinical trial is underway for GUB014295. GUB014295 is a calcitonin and amylin receptor-specific agonist that may be a long-acting amylin analog. Since amylin, a satiety hormone, acts as an inhibitory signal to delay gastric emptying and activates signals to the brain that suppress hunger and reduce food intake, it has been identified as a possible therapeutic target for the treatment of obesity.
Obesity represents a significant global health concern with nearly 900 million adults with obesity, many of whom struggle to stay on current treatment options,
Building on Gubra’s experience in the discovery of novel peptide-based therapeutics, we look forward to advancing the development of the GUB014295 program.
Roopal Thakkar, M.D., executive vice president, research & development, chief scientific officer, AbbVie
Also Read: BEACON-IPF Clinical Trial for Idiopathic Pulmonary Fibrosis Discontinued With Available Results
We are excited to partner with AbbVie given its strong capabilities in both the development and commercialization of life-changing medicines,
This collaboration between Gubra and AbbVie will accelerate the development of GUB014295 and build on the promising data shown in its Phase 1 single ascending dose (SAD) trial. Our team has been extremely impressed with AbbVie and their commitment to bring this important partnership to life. We look forward to working together throughout the development of the GUB014295 program.
Henrik Blou, chief executive officer, Gubra
Source: AbbVie News Centre
Last Modified:
